Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies

• Published in: Frontiers in cell and developmental biology Vol. 11; p. 1090046
• Main Authors: Roth, Charlotte, Kilpinen, Helena, Kurian, Manju A, Barral, Serena
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 27.02.2023
• Subjects: brain organoids; Cell and Developmental Biology; epigenetics (chromatin remodeling); histone lysine methyltransferases (HKMTs); neurodevelopmental disorders (NDDs); small-activating RNA (saRNA); epigenetics (chromatin remodeling); small-activating RNA (saRNA); histone lysine methyltransferases (HKMTs); brain organoids; neurodevelopmental disorders (NDDs)
• ISSN: 2296-634X; 2296-634X
• DOI: 10.3389/fcell.2023.1090046

Neurodevelopmental disorders encompass a group of debilitating diseases presenting with motor and cognitive dysfunction, with variable age of onset and disease severity. Advances in genetic diagnostic tools have facilitated the identification of several monogenic chromatin remodeling diseases that cause Neurodevelopmental disorders. Chromatin remodelers play a key role in the neuro-epigenetic landscape and regulation of brain development; it is therefore not surprising that mutations, leading to loss of protein function, result in aberrant neurodevelopment. Heterozygous, usually mutations in histone lysine methyltransferases have been described in patients leading to haploinsufficiency, dysregulated protein levels and impaired protein function. Studies in animal models and patient-derived cell lines, have highlighted the role of histone lysine methyltransferases in the regulation of cell self-renewal, cell fate specification and apoptosis. To date, in depth studies of histone lysine methyltransferases in oncology have provided strong evidence of histone lysine methyltransferase dysregulation as a determinant of cancer progression and drug resistance. As a result, histone lysine methyltransferases have become an important therapeutic target for the treatment of different cancer forms. Despite recent advances, we still lack knowledge about the role of histone lysine methyltransferases in neuronal development. This has hampered both the study and development of precision therapies for histone lysine methyltransferases-related Neurodevelopmental disorders. In this review, we will discuss the current knowledge of the role of histone lysine methyltransferases in neuronal development and disease progression. We will also discuss how RNA-based technologies using small-activating RNAs could potentially provide a novel therapeutic approach for the future treatment of histone lysine methyltransferase haploinsufficiency in these Neurodevelopmental disorders, and how they could be first tested in state-of-the-art patient-derived neuronal models.